Pier Giorgio Cojutti1,2, Matteo Rinaldi3,4, Eleonora Zamparini3,4, Nicolò Rossi3,4, Sara Tedeschi3,4, Matteo Conti3, Federico Pea5,6, Pierluigi Viale3,4. 1. Department of Medicine, University of Udine, Italy. 2. Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital of Udine, ASUFC, Udine, Italy. 3. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 4. Infectious Diseases Unit, IRCCS Sant' Orsola-Malpighi Teaching Hospital, Bologna, Italy. 5. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy federico.pea@unibo.it. 6. SSD Clinical Pharmacology Unit, IRCCS Sant' Orsola-Malpighi Teaching Hospital, Bologna, Italy.
Abstract
Background: Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infections.Objective: To conduct a population pharmacokinetic analysis of dalbavancin in a prospective cohort of adult patients with Gram-positive OA infections and to identify optimal dosing regimens for long term-treatment. Methods: Non-linear mixed-effects modelling was performed with Monolix. Monte Carlo simulations were performed with six dalbavancin regimens (1500mg at day 1; 1000mg at day 1 plus 500mg at day 8; 1500mg at day1 and 8; 1500mg at day1 and 8 plus 500, 1000 or 1500mg at day 36) to assess the PTA of three pharmacodynamic target of fAUC24h/MIC against S. aureus (>27.1, 53.3 and 111.1). Cumulative fraction of response (CFR) was calculated against MIC distribution of both MRSA and MSSA as well. Desirable PTAs and CFRs were ≥90%. Results: Fifteen patients provided 120 plasma concentrations. Most (73.3%) had prosthetic joint infections. Clinical cure rate was 87%. A two-compartment model with linear elimination well described the data. No covariate was retained in the final model. Pharmacokinetic dalbavancin estimates were 0.106L/h for CL and 36.4L for Vss The tested dosing regimens granted desirable CFRs against S. aureus at the most effective PK/PD target for a period ranging 3-to-9 weeks. Conclusion: Giving a two 1500mg dosing regimen of dalbavancin one week apart may ensure efficacy against both MSSA and MRSA up to 5 weeks in patients with OA infections. Clinical assessment at that time may allow for considering whether or not an additional dose should be administered for prolonging effective treatment.
Background: Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infections.Objective: To conduct a population pharmacokinetic analysis of dalbavancin in a prospective cohort of adult patients with Gram-positive OA infections and to identify optimal dosing regimens for long term-treatment. Methods: Non-linear mixed-effects modelling was performed with Monolix. Monte Carlo simulations were performed with six dalbavancin regimens (1500mg at day 1; 1000mg at day 1 plus 500mg at day 8; 1500mg at day1 and 8; 1500mg at day1 and 8 plus 500, 1000 or 1500mg at day 36) to assess the PTA of three pharmacodynamic target of fAUC24h/MIC against S. aureus (>27.1, 53.3 and 111.1). Cumulative fraction of response (CFR) was calculated against MIC distribution of both MRSA and MSSA as well. Desirable PTAs and CFRs were ≥90%. Results: Fifteen patients provided 120 plasma concentrations. Most (73.3%) had prosthetic joint infections. Clinical cure rate was 87%. A two-compartment model with linear elimination well described the data. No covariate was retained in the final model. Pharmacokinetic dalbavancin estimates were 0.106L/h for CL and 36.4L for Vss The tested dosing regimens granted desirable CFRs against S. aureus at the most effective PK/PD target for a period ranging 3-to-9 weeks. Conclusion: Giving a two 1500mg dosing regimen of dalbavancin one week apart may ensure efficacy against both MSSA and MRSA up to 5 weeks in patients with OA infections. Clinical assessment at that time may allow for considering whether or not an additional dose should be administered for prolonging effective treatment.
Authors: Abrar K Thabit; Dania F Fatani; Maryam S Bamakhrama; Ola A Barnawi; Lana O Basudan; Shahad F Alhejaili Journal: Int J Infect Dis Date: 2019-02-14 Impact factor: 3.623
Authors: Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson Journal: Clin Infect Dis Date: 2012-12-06 Impact factor: 9.079
Authors: Michael A Pfaller; Robert K Flamm; Mariana Castanheira; Helio S Sader; Rodrigo E Mendes Journal: Int J Antimicrob Agents Date: 2017-12-23 Impact factor: 5.283
Authors: Elie F Berbari; Souha S Kanj; Todd J Kowalski; Rabih O Darouiche; Andreas F Widmer; Steven K Schmitt; Edward F Hendershot; Paul D Holtom; Paul M Huddleston; Gregory W Petermann; Douglas R Osmon Journal: Clin Infect Dis Date: 2015-07-29 Impact factor: 9.079
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Brian J Werth; Nathaniel K Ashford; Kelsi Penewit; Adam Waalkes; Elizabeth A Holmes; Dylan H Ross; Tianwei Shen; Kelly M Hines; Stephen J Salipante; Libin Xu Journal: Clin Microbiol Infect Date: 2020-08-28 Impact factor: 13.310
Authors: S Baklouti; S Marolleau; P Chavanet; E Bonnet; D Concordet; P Gandia Journal: Antimicrob Agents Chemother Date: 2021-10-18 Impact factor: 5.938
Authors: Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita Journal: Antimicrob Agents Chemother Date: 2022-04-27 Impact factor: 5.938
Authors: Pier Giorgio Cojutti; Sara Tedeschi; Milo Gatti; Eleonora Zamparini; Marianna Meschiari; Paola Della Siega; Maria Mazzitelli; Laura Soavi; Raffaella Binazzi; Elke Maria Erne; Marco Rizzi; Anna Maria Cattelan; Carlo Tascini; Cristina Mussini; Pierluigi Viale; Federico Pea Journal: Antibiotics (Basel) Date: 2022-07-24